114 Views | 43 Downloads
Douglas K. Graham, AFLAC Cancer and Blood Disorders Center, 2015 Uppergate Drive, Atlanta, Georgia 30322, USA. Phone: 404.785.3874; Email: douglas.graham@choa.org
DY conceived the study, designed, performed, analyzed, and interpreted experiments, and wrote the manuscript. DKG and DD conceived the study, analyzed and interpreted experiments, and edited the manuscript. JMH performed and analyzed experiments. DK designed, performed, analyzed, and interpreted computational modeling. ZT, LC, and SG analyzed experiments. MB and FS provided patient samples and related clinical data. HSE, XW, and SVF provided suggestions for experiments and edited the manuscript. SSR and TO provided suggestions for experiments and clinical perspective and edited the manuscript. All authors read and agreed with the manuscript
This research was supported by the National Cancer Institute (NCI) of the National Institutes of Health (Emory University Lung Cancer SPORE, P50CA217691), Winship Cancer Institute #IRG-17-181-05 from the American Cancer Society, the Emory Lung SPORE Pathology Core, and the Winship Cancer Institute Biostatistics and Cancer Tissue and Pathology Shared Resources (P30CA138292). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors thank Rebecca Parker and Travon Baxter for technical support during animal studies and Arlen Ho for providing preliminary data related to this work.
DKG, SVF, and HSE are founders of Meryx Inc. DKG and SVF serve on the Board of Directors of Meryx Inc. SVF, HSE, DKG, DD, and XW are equity holders in Meryx Inc. The company’s key clinical candidate, MRX-2843, is evaluated in this research. XW and SVF are inventors on patents describing MRX-2843 (patent numbers listed in Supplemental Materials). DY, HSE, DD, and DKG are inventors on a patent (number US10709708B2 [to Emory University]) describing the use of MRX-2843 in combination with osimertinib. SSR has served on the Scientific Advisory Board and in a consulting role for AstraZenca and has also received research support (to Emory University) from AstraZeneca. TO has received research funding (to Emory University) from AstraZeneca in compensation for advisory board service.
The data included in this manuscript are the major data used for the funded Emory Lung Cancer Spore (P50CA217691) of Project 2.
© 2022, Yan et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.